Biosimilar versions of drugs like Humira, Eylea and Keytruda are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.

Coherus’ year-end financial results included a surprise – a newly approved formulation of pegfilgrastim.

Coherus BioSciences is feeling bullish about its potential in the biosimilar ophthalmology space after agreeing to bring on board a biosimilar Eylea (aflibercept) candidate, with an eye on launching potentially in 2025.

Having previously underlined that it would not tell the market the exact moment it filed its proposed biosimilar pegfilgrastim on-body injector device, Coherus BioSciences has now confirmed a filing was completed late last year.